Media

January 10 2025

Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310

MORE >

January 7 2025

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

MORE >

December 20 2024

Verismo Therapeutics Completes Merger to Accelerate Clinical Development

MORE >

October 8 2024

Verismo Therapeutics Announces the Activation of its CELESTIAL-301 Clinical Trial at Colorado Blood Cancer Institute

MORE >

September 17 2024

Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant

MORE >

May 14 2024

Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

MORE >

May 6 2024

Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024

MORE >

April 3 2024

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

MORE >

March 7 2024

Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial

MORE >

November 3 2023

Verismo Therapeutics Announces Upcoming Presentation at SITC 2023

MORE >